# FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Source: https://onco.cc/trials/nct05466799/  
OnCo record `nct05466799` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of FOLFIRINOX chemotherapy in pancreatic ductal adenocarcinoma, run by OncoSil Medical Limited, active and no longer recruiting.

## Summary

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma is a phase 2 interventional study registered as NCT05466799 by OncoSil Medical Limited, with 88 participants enrolled, started 2023-04-26 and due to reach its primary completion in 2026-01-26. Interventions recorded: FOLFIRINOX chemotherapy and OncoSil™.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05466799
- Phase: 2
- Setting: An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma.
- Sponsor: OncoSil Medical Limited
- Enrolled: 88

## Sources

- ClinicalTrials.gov NCT05466799: https://clinicaltrials.gov/study/NCT05466799

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct05466799.json